PERSPECTA

News from every angle

← Back to headlines

Halozyme (HALO) Stock Rated Buy on Strong Royalty Growth

Halozyme Therapeutics (HALO) has received a 'Buy' rating, driven by expectations of strong royalty growth.

2 May, 17:51 — 2 May, 17:51
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual96d ago

Halozyme (HALO) Rated Buy on Strong Royalty Growth

Read full article →

Related Stories

Benue Residents Campaign for Exclusive Breastfeeding

35m ago

Promising Heart Drug Fails, Challenging Disease Theory

1h ago

Nigeria Faces Relentless Heatwave as New Normal

2h ago

Record Heatwave Grips Asia, Raising Energy Crisis and Health Concerns

2h ago